ADC Development Services Targeting Cadherin 6

Currently, the targeted therapies for cancer especially antibody-drug conjugates (ADCs) are displaying remarkable advantages. A large number of ADCs have been developed in recent years, and several of them have been approved by the FDA for disease therapy in cancer patients. As one of the leaders in the field of bio-conjugation, Creative Biolabs has more than ten years of experience in the ADCs construction or other conjugates. We provide one-stop ADCs development services targeting the Cadherin-6 biomarker from design to quality analysis. We believe our featured services and solutions will meet your specific demands for successful ADCs preparation.

Introduction of Cadherin 6

Cadherin-6, also known as CDH6, is a type II classic cadherin encoded by the CDH6 gene. It is a member of the cadherin superfamily first described as K-cadherin. Cadherin-6 is a membrane glycoprotein composed of an extracellular cadherin, a transmembrane domain and a conserved cytoplasmic tail. The protein is mainly expressed in the kidney and central nervous system, while is highly expressed in fetal kidney and kidney carcinoma. Besides, it has also been found in ovarian and thyroid cancers. Cadherin-6 plays an important role in mediating the calcium-dependent cell-cell adhesion like other cadherin superfamily members. Importantly, it presents other properties including rapid internalization and membrane localization change in tumor cells, which highlights the advantage of Cadherin-6 as a potential target for targeted immunotherapy.

Cadherin-6 involves in the renal cell carcinoma (RCC).Fig.1 Cadherin-6 involves in the renal cell carcinoma (RCC). (Santoni, 2019)

Anti-Cadherin 6 ADC in RCC

Cadherin-6 as a promising target has been used in the ADC development for the RCC therapy. For example, HKT288 is a novel ADC based on the Cadherin-6, which comprises an anti-Cadherin-6 fully human antibody conjugated to a maytansine-derived cytotoxic drug, N2′-deacetyl-N2′-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4), through a hindered disulfide-based linker, N-succinimidyl 4-(2-pyridyldithio)-2-sulfobutanoate (sulfo-SPDB). Preclinical trials demonstrated that HKT288 can induce durable tumor regressions of ovarian and renal cancer models in vivo. Besides, the ADC showed a significant preclinical safety profile, which promotes the clinical assessment of HKT288. Currently, the ADC is under investigated in the Phase I actively.

 Overall structure of lead CDH6 antibody Fab fragment (show as ribbon) binding to CDH6 (shown as surface). Fig.2 Overall structure of lead CDH6 antibody Fab fragment (show as ribbon) binding to CDH6 (shown as surface). (Bialucha, 2017)

What Can We Do for You?

Over the past decade, Creative Biolabs is an undisputed global leader in the field of novel drug discovery and production. Our customers take advantage of our knowledge and competences to expedite their drug discovery programs. Recently, Creative Biolabs is committed to the ADC development services based on a variety of targets including Cadherin-6. Our professional technical scientists can not only save your valuable time but also provide highly effective and qualified products for our clients all over the world. If you are interested in our service, please do not hesitate to contact us for more details. Our ADCs construction services including:


  1. Santoni, M.; et al. Circulating Tumor Cells in Renal Cell Carcinoma: recent findings and future challenges. Frontiers in oncology. 2019, 9: 228.
  2. Bialucha, C. U.; et al. Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. Cancer discovery. 2017, 7(9): 1030-1045.

For lab research use only, not for any in vivo human use.

Related Sections

ADC Development for Renal Cancer: Disease Research:
Online Inquiry
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
UK - Germany